The global IgA nephropathy market is anticipated to witness steady growth from 2025 to 2035, driven by the growing incidence of chronic kidney diseases and the introduction of innovative, disease-modifying therapies. The market size is expected to increase from USD 46.82 billion in 2025 to USD 99.66 billion by 2035, expanding at a CAGR of 7.6%. The increasing availability of advanced diagnostic tools, a rise in disease awareness, and the launch of novel pharmacological solutions are shaping the future outlook for this market.
IgA Nephropathy Industry Assessment
| Attributes | Key Insights |
|---|---|
| Estimated Size, 2025 | USD 46.82 billion |
| Projected Size, 2035 | USD 99.66 billion |
| Value-based CAGR (2025 to 2035) | 7.6% |
Primary IgA nephropathy continues to dominate the disease type segment with a commanding 81.0% share in 2025. This is primarily due to its high prevalence in Asia Pacific and Western nations, as well as improvements in early disease detection using renal biopsy and proteinuria markers. On the other hand, secondary IgA nephropathy-though smaller in share-is gradually gaining clinical attention due to its association with systemic diseases like liver cirrhosis and inflammatory bowel disease.
Among end users, hospitals remain the largest segment, holding an estimated 62.1% market share in 2025. The availability of specialized nephrology care, integrated dialysis units, and access to new therapeutic interventions such as SGLT2 inhibitors and endothelin receptor antagonists support hospital dominance. Moreover, the growing participation of hospitals in global clinical trials enhances their role in IgA nephropathy care delivery.
A landmark industry development is shaping the market landscape. On October 2, 2023, Novartis AG officially announced positive topline results from its Phase III APPLAUSE-IgAN trial evaluating iptacopan (Fabhalta®) for IgA nephropathy. The study demonstrated a statistically significant 38.3% reduction in proteinuria at nine months compared to placebo, along with a favorable safety profile.
These results were disclosed via an official Novartis press release published on its corporate website and were widely covered by reputed sources such as FierceBiotech and PharmaTimes. Furthermore, the USA FDA granted accelerated approval for iptacopan in August 2024, validating its potential as the first targeted oral therapy for patients with progressive IgA nephropathy and setting a new benchmark in disease-specific treatment.
The below table presents the expected CAGR for the global IgA nephropathy market over several semi-annual periods spanning from 2025 to 2035. In the first half (H1) of the decade from 2024 to 2035, the business is predicted to surge at a CAGR of 8.3%, followed by a slightly lower growth rate of 8.0% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 8.3% (2024 to 2034) |
| H2 | 8.0% (2024 to 2034) |
| H1 | 7.6% (2025 to 2035) |
| H2 | 7.1% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 7.6% in the first half and decrease moderately at 7.1% in the second half. In the first half (H1) the market witnessed a decrease of 70.00 BPS while in the second half (H2), the market witnessed an increase of 90.00 BPS.
The section contains information about the leading segments in the industry. By disease type, the primary IgA nephropathy segment holds the highest market share of 81.0% in 2025.
| By Disease Type | Primary IgA Nephropathy |
|---|---|
| Value Share (2025) | 81.0% |
Primary IgA nephropathy comprises the majority in the market for it has greater prevalence compared with the secondary manifestation of the disorder. Primary IgA nephropathy is an international leading condition for glomerulonephritis, caused through the deposition of IgA onto the kidneys due to which causes inflammation and harm. It holds a growing propensity in regions including Asia and Europe, making significant attention towards such research and potential treatments.
The market is driven by a higher number of diagnosed cases of primary IgA nephropathy, as it typically presents with symptoms like hematuria and proteinuria, prompting early medical intervention.
Moreover, advancements in diagnostic techniques and targeted therapies are primarily focused on primary IgA nephropathy, leading to more effective management and treatment. The growing awareness for this disease, along with new therapeutics emerging for primary IgA nephropathy, is also a harbinger of the company's dominance in the market.
| By End User | Hospitals |
|---|---|
| Value Share (2025) | 62.1% |
Hospitals are the market leaders in terms of end-user, as these institutions have vast medical infrastructure, and specialized departments of nephrology are readily available.
Among the hospitals, tertiary and quaternary care centers are advanced in terms of diagnostic tools such as kidney biopsy, imaging technologies, and biomarker-based tests, which is a must for the proper diagnosis of IgA nephropathy. In addition, hospitals offer full ranges of treatment and therapies such as immunosuppressive drugs, biologics, dialysis, making the treatment more efficient in disease management.
Factors that prove to increase hospitals' share in the market include the availability of experienced nephrologists and the capacity for acute care of cases of IgA nephropathy when they get severe.
As the disease progresses, patients tend to have to be hospitalized for treatment-related complications, especially towards the end. Further, clinical trials for novel therapies for IgA nephropathy are usually done in hospitals, hence increasing growth in the market's hospital segment.
Advancements in Biomarker Discovery for Early Diagnosis Is Driving the Growth for IgA Nephropathy Market.
Biomarker discovery advancement, especially in galactose-deficient IgA1, is revolutionizing early diagnosis and management of IgA nephropathy, and hence, serves as a critical market driver. Gd-IgA1 has emerged as an important biomarker closely linked to the disease's pathophysiology.
Early identification of raised Gd-IgA1 levels not only aids in the stratification of patients according to the severity of disease but also assists in decisions about therapy. For example, with the use of biomarkers for targeting therapies directed against complement pathway activation, optimization of clinical benefits can be expected without adverse effects related to generalized immunosuppression.
Notably, technological advancements in diagnostic tools, including liquid biopsies and high-throughput mass spectrometry, will make it even easier for Gd-IgA1 assays to be introduced into clinical practice. Biomarker testing will become more easily accessible, reliable, and cost-effective, thus reinforcing the incorporation of this type of testing among healthcare providers.
Increased awareness and adoption of biomarker-based diagnostics also drive research into other potential biomarkers, expanding the scope of early detection and personalized treatment options. As these developments gain traction, they enhance the overall treatment paradigm for IgA nephropathy, significantly contributing to market growth.
Expansion of Clinical Trials Is Favoring Disease Management and Future Growth for IgA Nephropathy Market
The expansion of clinical trials is the other big driver of the IgA nephropathy market, speeding up the development and approval of innovative treatments. Because the pathophysiology of the disease is better understood, clinical trials increasingly focus on exploring targeted therapies associated with specific mechanisms, including immune modulation and complement pathway inhibition.
This increased number of trials reflects interest from pharmaceutical companies and research institutes in treating the chronic kidney disease, which long remained an undertreated chronic kidney condition by currently available therapies.
These trials are also important for evaluating novel therapeutics, including biologics, small molecules, and combination treatments. For example, therapies like narsoplimab, iptacopan, and atacicept are undergoing rigorous studies to change the current treatment paradigm.
Other expanded clinical research efforts include adaptive trial designs and real-world evidence studies, which shorten development timelines and improve the relevance of trial outcomes to everyday clinical practice.
Regulatory incentives include orphan drug designations and fast-track approvals. These help strengthen the growth in clinical trials, as investor confidence is enhanced along with market interest. This expanding pipeline of therapies resulting from clinical research is going to improve the management of disease, and the resulting growth is significant for the IgA nephropathy market.
The Increasing Preference for Drugs Over Dialysis Is Emerging as A Significant Driver in The IgA Nephropathy Market
Traditionally, for patients with advanced IgA nephropathy progressing to end-stage renal disease, the only hope for survival would be dialysis or kidney transplantation. However, these treatments involve many limitations and drawbacks, which include invasive procedures, high costs, and severe effects on quality of life caused by time-consuming and physically stressing processes.
On the contrary, innovative pharmacological treatments allow patients to opt for a less invasive, more manageable alternative, which may delay or prevent the requirement for dialysis.
Targeted drugs in the form of specific pathways include complement system inhibitors, B-cell modulators, and other biologics, which can slow disease progression, reduce proteinuria, and preserve kidney function. Oral small-molecule drugs and long-acting biologics make patients' lives more convenient, which improves adherence and treatment outcomes.
This shift in preference is backed by healthcare providers and payers who realize the cost-effectiveness and greater accessibility of pharmacological treatment over long-term dialysis. Further, increased availability of targeted therapies, owing to the growth in precision medicine and biomarker discovery, has led to increasing individualization of drug-based treatment options, offering higher efficacy and safety.
Increases in awareness of these benefits will mean a higher demand for drug therapies over dialysis, thereby fostering innovative solutions, improved adoption among patients, and greater overall market growth in the treatment of IgA nephropathy.
Limited Pipeline Diversity Is Emerging as Significant Growth Barrier for IgA Nephropathy Market Growth
This limited diversity in the therapeutic pipeline of IgA nephropathy has been a significant restraint in the market, restricting the development of a wide variety of treatment options for healthcare providers. Although increasing interest in IgA nephropathy has driven some progress, the pipeline remains relatively narrow in comparison to other chronic kidney diseases.
This is because IgA nephropathy is considered a complex disease, with heterogeneity and complexity in the target underlying mechanisms that pose a significant challenge in trying to intervene against it. With fewer new therapeutic agents under development, options are limited for clinicians.
The lack of alternative treatments further challenges the healthcare professional in attending to the diverging needs of various patients. A single patient is unlikely to benefit from every kind of treatment and, more likely, will benefit more from only some of the various treatments than another.
Further, the low numbers of drugs in development and entering the market are those targeted towards different aspects of the disease such as immune modulation, complement system regulation, and even fibrosis prevention. This limits the effectiveness of treatment strategies, especially in cases with more aggressive disease progression.
The relatively slow development of diverse drug candidates also impacts market growth by maintaining reliance on older, less effective therapies and off-label treatments. For IgA nephropathy, increasing the pipeline diversity is crucial to advancing treatment standards and improving patient outcomes.
Tier 1 companies comprise market leaders with a significant market share of 58.9% in global market. These companies engage in strategic partnerships and acquisitions to expand their product portfolios and access cutting-edge technologies. Additionally, they emphasize extensive clinical trials to validate the efficacy and safety of their products. Prominent companies in tier 1 include Novartis AG, Sanofi S.A. and AstraZeneca
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 21.9% market share. They typically pursue partnerships with multispecialty hospitals and research organizations to leverage emerging technologies and expedite product development.
These companies often emphasize agility and adaptability, allowing them to quickly bring new products to market, additionally targeting specific types medical needs. Additionally, they focus on cost-effective production methods to offer competitive pricing. Prominent companies in tier 2 include Takeda Pharmaceutical Company Limited and Pfizer Inc.
Finally, Tier 3 companies, such as G Validus Pharmaceuticals LLC and Organon Group of Companies. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the IgA nephropathy sales remains dynamic and competitive.
The section below covers the industry analysis for the IgA nephropathy market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle Ease & Africa, is provided.
The United States is anticipated to remain at the forefront in North America, with higher market share through 2035. In South Asia & Pacific, India is projected to witness a CAGR of 9.1% by 2035.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 6.2% |
| Germany | 4.4% |
| China | 9.0% |
| France | 2.4% |
| India | 9.1% |
| Spain | 5.7% |
| Australia & New Zealand | 6.5% |
| South Korea | 6.0% |
United States. IgA nephropathy market is poised to exhibit a CAGR of 6.2% between 2025 and 2035. Currently, it holds the highest share in the North American market.
There has been a rapidly developing pharmaceutical and biotechnology sector in the USA One of the big factors driving this market is in the USA, where one finds many giant pharmaceutical and biotech companies focused in R&D innovative treatment for IgA nephropathy.
The USA has a established R&D infrastructure, with increased investment in research and technology besides infrastructural advances, ensuring continuity in innovation activities. In-depth collaboration between business leaders and academy accelerates discovering new treatments of the disease leading to new IgA nephropathy therapies.
These companies are at the forefront of advancing therapies, especially biologics and small molecules, which target the underlying disease mechanisms, such as complement activation and immune modulation.
Such an atmosphere does not only deep the clinical trials and testing but also ensures a steady flux of breakthroughs that position the USA on top of the IgA nephropathy market in the rest of the world.
Germany’s IgA nephropathy market is poised to exhibit a CAGR of 4.4% between 2025 and 2035. Currently, it holds the highest share in the Western Europe market, and the trend is expected to continue during the forecast period.
Leading research and development in Germany are major impetus factors behind the country's supremacy in the IgA nephropathy market. Germany is well known for its medical research focus, especially in rare diseases like IgA nephropathy. It hosts top research centers and universities working on understanding the condition better and creating new therapies for it.
Further facilitating accelerated innovation in the development of treatments is the collaborative environment created between academia, biotechnology, and the pharmaceutical industry. Translating the basic scientific discovery into clinical trials and therapies, these collaborations have been very beneficial in helping bridge the unmet needs of the patients suffering from IgA nephropathy.
The continuous innovation along with the leading researchers places Germany at the forefront of advancing the IgA nephropathy market and new therapies that bring improvement to the patient's outcome.
India IgA nephropathy market is poised to exhibit a CAGR of 9.1% between 2025 and 2035. Currently, it holds the highest share in the South Asia & Pacific market, and the trend is expected to continue during the forecast period.
The high patient cases requiring organ transplants significantly impact the growth rate of the market for IgA nephropathy. Due to the gigantic and increasing population that is afflicted increasingly with chronic disorders such as diabetes, hypertension, and liver, the demand for organs has seen immense growth. Hence, there exists a waiting list of growing size for the increase in number of patients to require kidney, liver, and other organ transplants.
A large patient pool necessitates effective and reliable transport systems to ensure that donated organs are preserved under optimal conditions during transit, especially in a vast country like India.
The need for advanced transport devices is heightened because healthcare providers want to reduce the transplant rejection rate and improve the outcomes of the patients. This growing patient pool continues to drive the demand for innovative organ transport technologies in India.
The market players are using strategies to stay competitive, such as product differentiation through innovative formulations, strategic partnerships with healthcare providers for distribution.
Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence.
Recent Industry Developments in IgA Nephropathy Market
| Report Attributes | Details |
|---|---|
| Market Size (2025) | USD 46.82 billion |
| Projected Market Size (2035) | USD 99.66 billion |
| CAGR (2025 to 2035) | 7.6% |
| Base Year for Estimation | 2024 |
| Historical Period | 2020 to 2024 |
| Projection Period | 2025 to 2035 |
| Quantitative Units | USD billion for Value & Thousand Units for Volume |
| Diagnosis & Treatment (Segment 1) | Diagnosis, Treatment |
| Disease Type (Segment 2) | Primary IgA Nephropathy, Secondary IgA Nephropathy |
| Indication (Segment 3) | Hematuria, Proteinuria, Hypertension, Edema, Others |
| Population Type (Segment 4) | Pediatrics, Adults |
| Route of Administration (Segment 5) | Oral, Parenteral |
| End User (Segment 6) | Hospitals, Specialty Clinics, Homecare, Others |
| Regions Covered | North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia, Middle East & Africa |
| Countries Covered | United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, South Korea, India, ASEAN Countries, GCC Countries, South Africa |
| Key Players influencing the Market | Novartis AG, Sanofi S.A., AstraZeneca, Takeda Pharmaceutical Company Limited, Pfizer Inc., Validus Pharmaceuticals LLC, Organon Group of Companies |
| Additional Attributes | Dollar sales, share, Novel immunosuppressive therapies development, Increasing prevalence among adults, Significant clinical trials in secondary IgA nephropathy, Rising oral treatment preference, Hospital-based diagnosis dominates, Homecare showing growth. |
In terms of diagnosis & treatment, the industry is divided into- diagnosis and treatment.
In terms of disease type, the industry is segregated into- primary IgA nephropathy and secondary IgA nephropathy.
In terms of indication, the industry is segregated into- hematuria, proteinuria, hypertension, edema and others.
In terms of population type, the industry is segregated into- pediatrics and adults.
In terms of route of administration, the industry is segregated into- oral and parenteral.
In terms of end user, the industry is segregated into- hospitals, specialty clinics, homecare and others.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global IgA nephropathy market is projected to witness CAGR of 7.6% between 2025 and 2035.
The global IgA nephropathy industry stood at USD 43.8 billion in 2024.
The global IgA nephropathy market is anticipated to reach USD 99.66 billion by 2035 end.
India is set to record the highest CAGR of 9.1% in the assessment period.
The key players operating in the global IgA nephropathy market include Novartis AG, Sanofi S.A., AstraZeneca, Takeda Pharmaceutical Company Limited, Pfizer Inc., Validus Pharmaceuticals LLC and Organon Group of Companies.
Explore Similar Insights
IgA Nephropathy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
